Table 2.
Clinical trials of VEGF/VEGFR inhibitors
| Name | Additional agents | Status | Disease | References |
|---|---|---|---|---|
| AG013736 | II | RCC | Rini et al. 2009 | |
| AMG 706 | II | Thyroid cancer | Sherman et al. 2008 | |
| AMG 706 | I | Solid tumor | Rosen et al. 2007 | |
| AZD2171 | II | GBM | Batchelor et al. 2010 | |
| AZD2171 | Gefitinib | I | Solid tumors | van Cruijsen et al. 2010 |
| AZD2171 | I | AML | Fiedler et al. 2010 | |
| AZD2171 | I | Solid tumors | Drevs et al. 2007 | |
| BAY 57-9352 | I | Solid tumors | Eskens et al. 2009 | |
| Bevacizumab | Erlotinib | II | Biliary cancer | Lubner et al. 2010 |
| Bevacizumab | Erlotinib | I/II | Squamous cell cancer | Cohen et al. 2009a |
| Bevacizumab | Erlotinib | II | Breast cancer | Dickler et al. 2008 |
| Bevacizumab | Metronomic therapy | II | Breast cancer | Garcia-Saenz et al. 2008 |
| Bevacizumab | ± IFN-α 2b | II | Melanoma | Varker et al. 2007 |
| Bevacizumab | Oxaliplatin and capecitabine + XRT | I | Rectal cancer | Czito et al. 2007 |
| Bevacizumab | ± Interferon-a | III | RCC | Rini et al. 2008 |
| Bevacizumab | III | ADM | Patel et al. 2008 | |
| Bevacizumab | II | Ovarian | Burger et al. 2007 | |
| Bevacizumab | III | ADM | Scott et al. 2007 | |
| Bevacizumab | + Gemcitabine | II | Pancreatic | Kindler et al. 2005 |
| Bevacizumab | I-Peds | Solid tumor | Glade Bender et al. 2008 | |
| Bevacizumab | + Irinotecan | II-Peds | HGG | Gururangan et al. 2010 |
| GW786034 | II | GBM | Iwamoto et al. 2010 | |
| GW786034 | II | RCC | Hutson et al. 2010 | |
| HuMV833 | I | Solid tumor | Jayson et al. 2005 | |
| JNJ-26483327 | I | Solid tumors | Konings et al. 2010 | |
| MLN518 | II | Renal cell | Shepard et al. 2010 | |
| Pegaptanib (aptamer) | II | ADM | Apte et al. 2007 | |
| PKC412 | I | Advanced cancer | Fabbro et al. 2000 | |
| PTK 787/ZK 222584 | Cetuximab | I | Solid tumors | Langenberg et al. 2010 |
| PTK 787/ZK 222584 | Tem + XRT | I/II | GBM | Brandes et al. 2010 |
| PTK 787/ZK 222584 | + Pemetrexed + cisplatin | I | Solid tumor | Sharma et al. 2009 |
| PTK 787/ZK 222584 | I | Myelofibrosis with myeloid metaplasia | Giles et al. 2007 | |
| PTK 787/ZK 222584 | I | AML | Roboz et al. 2006 | |
| PTK 787/ZK 222584 | I | Liver metastases | Mross et al. 2005 | |
| PTK 787/ZK 222584 | I | Advanced cancer | Thomas et al. 2005 | |
| Ranibizumab | III | ADM | Kaiser et al. 2007a,b; Boyer et al. 2009; Bressler et al. 2009; Brown et al. 2009; Lalwani et al. 2009; Campochiaro et al. 2010; Sadda et al. 2010 | |
| SU11248 | II | NSCLC | Socinski et al. 2008; Ping et al. 2010 | |
| SU11248 | II | Cervical carcinoma | Mackay et al. 2010 | |
| SU11248 | II | Head and neck | Fountzilas et al. 2010 | |
| SU11248 | II | RCC | Motzer et al. 2006; Polyzos 2008; Kontovinis et al. 2009 | |
| SU11248 | II | Neuroendocrine cancer | Kulke et al. 2008 | |
| SU11248 | II | Breast cancer | Burstein et al. 2008 | |
| SU11248 | II | Urothelial cancer | Bradley et al. 2007 | |
| SU11248 | I | AML | Fiedler et al. 2005 | |
| SU5416 | I-peds | Brain tumor | Kieran et al. 2009 | |
| SU5416 | + Irinotecan | I | Colorectal | Hoff et al. 2006 |
| SU5416 | + Thalidomide | II | Melanoma | Mita et al. 2007 |
| SU5416 | II | Head and neck | Fury et al. 2007 | |
| SU5416 | I | Solid tumor | O’Donnell et al. 2005 | |
| SU5416 | I | Head and neck | Cooney et al. 2005 | |
| SU5416 | I | Sarcoma | Heymach et al. 2004 | |
| SU5416 | II | Melanoma | Peterson et al. 2004 | |
| SU5416 | II | Prostate cancer | Stadler et al. 2004 | |
| SU5416 | II | AML | O’Farrell et al. 2004 | |
| SU5416 | II | Multiple myeloma | Zangari et al. 2004 | |
| SU5416 | + IFN | II | RCC | Lara et al. 2003 |
| SU5416 | II | AML | Fiedler et al. 2003 | |
| SU5416 | II | RCC, sarcoma | Kuenen et al. 2003 | |
| SU5416 | II | Myeloproliferative disease | Giles et al. 2003a | |
| SU5416 | II | AML | Giles et al. 2003b | |
| Trap-Eye | I | ADM | Nguyen et al. 2009 | |
| VEGF Trap | I | Solid tumors | Lockhart et al. 2010 | |
| ZD6474, Zactima | ± Paclitaxel + carboplatin | II | NSCLC | Heymach et al. 2008 |
| ZD6474, Zactima | II | Multiple myeloma | Kovacs et al. 2006 | |
| ZD6474, Zactima | I | Solid tumors | Holden et al. 2005 | |
| ZD6474, Zactima | II | Breast cancer | Miller et al. 2005b | |
| ZD6474, Zactima | + XRT | II-Peds | HGG | Broniscer et al. 2010 |
| ZD6474, Zactima | + Vinorelbine/cisplatin or gemcitibine/cisplatin | I | NSCLC | Blackhall et al. 2010 |
| ZD6474, Zactima | Docetaxel ± | III | NSCLC | Herbst et al. 2010 |
| ZD6474, Zactima | II | Medullary thyroid cancer | Robinson et al. 2010a | |
| ZD6474, Zactima | + XRT + temozolomide | I | GBM | Drappatz et al. 2010 |
| ZD6474, Zactima | II | Ovarian | Annunziata et al. 2010 | |
| ZD6474, Zactima | II | Medullary thyroid cancer | Wells et al. 2010 | |
| ZD6474, Zactima | + Docetaxel/prednisolone | II | Prostate | Horti et al. 2009 |
| ZD6474, Zactima | Versus gefitinib | II | NSCLC | Natale et al. 2009 |
| ZD6474, Zactima | + FOLFIRI | I | Colorectal | Saunders et al. 2009 |
| ZD6474, Zactima | + Pemetrexed | I | NSCLC | de Boer et al. 2009 |
| ZD6474, Zactima | + mFOLFOX6 | I | Colorectal | Michael et al. 2009 |
| ZD6474, Zactima | II | NSCLC | Arnold et al. 2007; Kiura et al. 2008 | |
| ZD6474, Zactima | ± Docetaxel | II | NSCLC | Heymach et al. 2007 |
| ZD6474, Zactima | I | Solid tumor | Tamura et al. 2006 | |
| ZD6474, Zactima | II | NSCLC | Lee 2005 |